Peptide directoryHeart, vessels & kidneys

Vasostatin-1

The first 76 residues of chromogranin A, which loosen tight arteries.

Where it comes from

Made in
Chromaffin cells, sympathetic nerves and the heart, cut from chromogranin A
Sent out by
With catecholamines; chromogranin A rises in heart failure and sepsis
Acts on
  • Arteries
  • Heart muscle
  • Endothelium
  • Microbes

What it does

  • Relaxes vessels already constricted by noradrenaline or endothelin, including human veins stripped of their endothelium 1
  • Weakens the heartbeat and counters adrenaline on the heart 2
  • Antimicrobial in the laboratory, as several granin fragments are 2

In medicine

  • No medicine and no test for the fragment. Chromogranin A itself is measured as a neuroendocrine tumour marker, and that number reflects the whole protein and all of its pieces together 2
  • Chromogranin A rises in heart failure, sepsis and kidney failure, and on proton pump inhibitors; none of that says how much vasostatin-1 is present 2
  • The assays are the obstacle. Vasostatin-1 is the front of chromogranin A, so an antibody raised to it also binds the uncut protein, and reported levels depend on which antibody was used 2

Beyond the body’s own use

  • The vascular work is isolated tissue and animals: synthetic fragments from the start of chromogranin A relaxed constricted human saphenous vein, and that result from 1994 is still the anchor of the literature. No human study has followed it 1
  • Nothing is in trials and nothing is claimed for it. What a reader should take from the granin fragments is that activity in a dish is easy to show and hard to turn into a number in a patient 2

Sources

  1. Angeletti et al., Vasoinhibitory activity of synthetic peptides from the amino terminus of chromogranin A, Acta Physiologica Scandinavica 1994
  2. Troger et al., Granin-derived peptides, Progress in Neurobiology 2017

This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.